Roche Holding Ltd · SIX:RO
Roche — Investor Day (November 2021)
84 slides from Roche's investor day presentation, Nov 17, 2021
Slide 1: Digitalization along the value chain
Digitalization along the value chain Investor Relations Event 17 November 2021
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Agenda
Agenda Welcome • Karl Mahler, Head of Investor Relations Digitalization along the value chain • Alan Hippe; Chief Financial and IT Officer Roche Digitalization to improve disease understanding, identify new drug targets and leads • Mark McCarthy, Executive Director Human Genetics, gRED Digitalizatio
Slide 4: Alan Hippe | Chief Financial and IT Officer Roche
Digitalization along the value chain Alan Hippe| Chief Financial and IT Officer Roche 4
Slide 5: Industry trends: Our environment is changing at high pace
Industry trends: Our environment is changing at high pace Roche: Entering new frontiers by providing a digital infrastructure to match changing business needs A look into the future 5
Slide 6: Industry disruptions – trends impacting our core business dynamics
Industry disruptions – trends impacting our core business dynamics Care pathway and delivery Care pathway Prevention Diagnosis Treatment Pharma & medical 5 Trends: products (e.g., drugs & core pharma & diagnostics 1. Companies go beyond the pill – diagnostic tools) try direct to patient approaches 2
Slide 7: Digital maturity in Pharma relatively low compared to other industries
Digital maturity in Pharma relatively low compared to other industries Some improvement over the recent past DAI* Change 2020-2021 0 (low maturity) 50 100 (high maturity) All Industries PH 20 TE PS Asia 59 +4 EN IN PH 21 HC FI TC PH 20 PS FI EU IN TE TC 54 +3 PH 21 HC EN Possible explanation of
Slide 8: Digital Health: Capital flows reflect long term growth trends
Digital Health: Capital flows reflect long term growth trends and have spiked through the pandemic $15B $14.6B $14.7B $10B TOTAL $8.3B $7.8B VENTURE $6.0B FUNDING $4.5B $4.7B $4.6B $5B $2.1B $0B 2013 2014 2015 2016 2017 2018 2019 2020 2021 H1 NUMBER 196 294 323 342 374 383 383 460 376 OF DEALS AVERA
Slide 9: Well funded digital health players focused on serving the BioPharma industry
… there are also many well funded digital health players focused on serving the BioPharma industry Value Chain Discovery Development Operations Go-to-market Discover target areas Validate clinically Manufacture and Secure market access and products and operationally distribute products and drive ado
Slide 10: Today's magnitude of digital across Roche
Today’s magnitude of digital across Roche More than CHF 3bn annual spend in digital across the company Recent digital & PHC deals and partnerships1 CHF 3bn+ 300+ annual spend in digital key initiatives ongoing 50+ 30+ partnerships across data, analytics and digital supporting our continued focus sol
Slide 11: Digitalization along the value chain
Digitalization along the value chain 27 Diverse use cases presented today show the depth & breadth of digitalization Digital Infrastructure & Group functions 1 2 25 Treatment Clinical Regulatory & Manufacturing Diagnosis Support Early R&D Commercialization Development Reimbursement & Distribution Ph
Slide 12: Industry trends: Our environment is changing at high pace
Industry trends: Our environment is changing at high pace Roche: Entering new frontiers by providing a digital infrastructure to match changing business needs A look into the future 12
Slide 13: Vision: From data to insights
Vision: From data to insights Empowering domains to manage their own data, while promoting sharing, discovery of data & insights across the enterprise ... HR Manufacturing & supply Clinical chain Digital informatics Digital labs Research & product supply Commercial & medical RWD Converge within Dist
Slide 14: Example: Data to enable integrated use cases
Example: Data to enable integrated use cases Cross-functional integrated data Consume data products to support Clinical trials & Digital customer programs that require integrating biomarker data sharing engagement data across domains Data products Expose commonly used data as data Study Genomics Ima
Slide 15: Finance: A new data infrastructure
Finance: A new data infrastructure Enabling the business to meet their analytic and insight needs From a fragmanted infrastructure... …to a seamless data infrastructure Solution / Solution / Solution / Solution / Solution / Solution / application application application application application appli
Slide 16: Example: Creating a digital backbone in Finance
1 Example: Creating a digital backbone in Finance Business insights • Intuitive user experience consistent across devices • Support of new business models • Support mergers & acquisitions Speed & flexibility Risk & compliance • Continuous accounting and controls • Immediate financial analysis monito
Slide 17: Summary digital in Finance: Creating a digital backbone with ASPIRE
1 Summary digital in Finance: Creating a digital backbone with ASPIRE Amongst SAP’s 1 largest 1 ~350 enterprise-wide Process house across Program team S/4HANA projects program Roche colleagues across the worldwide globe Deployment planned to ~700 ~100.000 ~200 level 4 processes End users in scope le
Slide 18: Co-innovation with SAP & industry consortium
1 Co-innovation with SAP & industry consortium Clinical supply industry solution (CTSM) Intelligent clinical supply management (ICSM)1 Co-innovation as an industry consortium Building a clinical industry standard solution to supply clinical trials in collaboration with industry consortium: • Maximiz
Slide 19: Value creation through digitalization: myBuy in Finance
2 Value creation through digitalization myBuy in Finance New global purchasing platform driving easier, faster & more customer focused buying What have we achieved so far? New technology Suppliers • myBuy platform live since July 2020 with myBuy replaces multiple New portal to foster strong user ado
Slide 20: Roche's journey towards the cloud
Roche’s journey towards the cloud • Increasing number of applications are adopting cloud-based platforms • Increasing external collaborations require data and insights that can easily be shared (in a neutral environment), need cloud-based capabilities to support “neutral zones” • Support for multipl
Slide 21: Industry trends: Our environment is changing at high pace
Industry trends: Our environment is changing at high pace Roche: Entering new frontiers - providing a digital infrastructure to match changing business needs A look into the future 21
Slide 22: What digitalization delivers to Roche, healthcare systems and patients
Digitalization along the value chain What digitalization delivers to Roche, healthcare systems and patients Digital Infrastructure & Group functions Treatment Clinical Regulatory & Manufacturing Support Early R&D Commercialisation Diagnosis Development Reimbursement & Distribution Physicians & Patie
Slide 23: Mark McCarthy | Executive Director Human Genetics, gRED
Digitalization to improve disease understanding, identify new drug targets and leads Mark McCarthy| Executive Director Human Genetics, gRED 23
Slide 24: Digitalization impacting our entire value chain
Digitalization impacting our entire value chain Digital Infrastructure & Group functions 1 2 25 Treatment Clinical Regulatory & Manufacturing Diagnosis Support Early R&D Commercialization Development Reimbursement & Supply Physicians & Patients 3 4 5 9 10 11 12 13 14 24 17 21 26 27 12 19 23 6 7 8 15
Slide 25: Levers to transform drug discovery
Levers to transform drug discovery Multiplicative levers to transform understanding of disease biology and our capacity to modify causal pathways Delivering more medicines Focus on a diversity of for less cost to society digital data 25
Slide 26: Meaningful data at scale
Meaningful data at scale Integrate complementary, longitudinal data at scale Clinical data Omics Imaging Digital tools (trial & RWD) (genomics; (patient generated) transcriptomics; proteomics; metabolomics) Enable understanding of patient and disease heterogenity and its relevance to clinical outcom
Slide 27: A diversity of data
A diversity of data Human genetics is in vivo functional biology in the species we most care about Nelson, Nat Gen, 2015; King, PLoS Genetics, 2019 Wang et al, Nature, 2021 Natural experiments Clinical experiments of genetic perturbation of therapeutic perturbation Targets with human genetic support
Slide 28: The search for human diversity just started
The search for human diversity just started • Diversity • Power for discovery • Greater clinical relevance • Integration with health care Mutations in every one of the 3 billion bases in the human genome (provided compatible with life) is present in dozens of people on the globe 28
Slide 29: Human genetics help uncover potential new drug targets
3 Human genetics help uncover potential new drug targets ANGPTL7 loss of function mutation protects against glaucoma PheWAS in UK Biobank • Using genotyping data from the UK Biobank (n=337.151) and FinnGen (n=176.899) a search for protein-altering variants conferring lower intraocular pressure and p
Slide 30: Human genetics impact responses to checkpoint inhibition
4 Human genetics impact responses to checkpoint inhibition Tecentriq induced thyroid dysfunction associated with improved OS Meta-analysis on 7 Tecentriq trials across 6 different cancer types Meta-analysis of fraction of Meta-analysis for HR (OS) Hypothyroidism events in 7 trials Overall survival (
Slide 31: Single cell RNA transcription profiling
5 Single cell RNA transcription profiling Mapping the biological impact of COVID-19 infection in human cell types Isolation of single infected lung cells and gene expression profiling Single cell sampling of COVID-19 infected and uninfected lung cells Gene expression up/downregulation in COVID-19 in
Slide 32: Advances in computing and math make the bigness of biology a new advantage
Advances in computing and math make the bigness of biology, chemistry and medicine a new advantage Potential breakthrough goal: be predictive and explanatory (mechanistic) in biology, chemistry and medicine 32 32
Slide 33: Antibiotics discovery: ML improves virtual drug screening
6 Antibiotics discovery Machine learning and artificial intelligence improve virtual drug screening Virtual drug screening Applying AI and ML to virtual drug screening HTS for the identification of compounds inhibiting bacterial growth We've been working on virtual screening for decades, with a leve
Slide 34: Antibiotics discovery: Identifying new lead structures
6 Antibiotics discovery Identifying new lead structures with antibacterial properties Virtual screen successfully clusters known antibiotics Clustered known antibiotics Clustered known antibiotics colored according to class colored according to drug target • An algorithm applying AI and ML and train
Slide 35: Future of digital data in early research
Future of digital data in early research Human biology, high resolution and massive scale methods • Novel disease pathways • Oncogene coding • Acceleration of biological insights variants classes • Cell therapy states • Systematic discovery of targets and biomarkers • Gene therapy • More efficient t
Slide 36: Christian Gossens | Digital Biomarkers, Global Area Head, pRED
Digitalization to enable early R&D and clinical development Christian Gossens| Digital Biomarkers, Global Area Head, pRED 36
Slide 37: Digitalization impacting our entire value chain
Digitalization impacting our entire value chain Digital Infrastructure & Group functions 1 2 25 Treatment Clinical Regulatory & Manufacturing Support Early R&D Commercialization Diagnosis Development Reimbursement & Distribution Physicians & Patients 3 4 5 9 10 11 12 13 14 24 17 21 26 27 12 19 23 6
Slide 38: pRED Digital strategy
pRED Digital strategy Transform the scientific and Better understand patients and Optimise the pRED research experience the science behind the diseases operational engine • Increase the power of predictive • Gain deeper insights into patient • Deliver easy access to data and algorithms needs and the
Slide 39: One-D: Investing to sustainably increase pRED's productivity
One-D: Investing to sustainably increase pRED’s productivity TARGET LEAD LEAD PHASE 0 PHASE 1 PHASE 2 ASSESSMENT IDENTIFICATION OPTIMISATION AutoFAIR Digital Pathology Clinical Platforms Modeling & Simulation Quantum Computing Artificial Intelligence (AI) Productivity Driving fundamental shift Incre
Slide 40: Roche pRED Quantum Computing Taskforce
7 Roche pRED Quantum Computing (QC) Taskforce Evaluate QC to simulate drug action on proteins and to accelerate machine learning • Established 2.5 years ago • Explore if quantum advantage* exists for Roche relevant use cases • Understand QC hardware approaches and software (algorithms) and contribut
Slide 41: pRED in vivo research moved to an award winning facility
8 pRED in vivo research moved to an award winning facility Fully automated cage preparation Digitally controlled in vivo laboratories • Reducing manual labour and improving occupational • Enabling complete, precise control of the lab environment in hygiene for researchers which experiments are condu
Slide 42: Image analysis and machine learning in ophthalmology
9 Image analysis and machine learning in ophthalmology Non-invasive, automatic identification of lesion type in nAMD using deep learning • Neovascular AMD (nAMD) manifests in different types, which are important biomarkers for tailored treatment • The assessment uses an invasive, slow, and costly “c
Slide 43: Digital endpoints to drive scientific progress
Digital endpoints to drive scientific progress Delivering new patient insights and building holistic solutions for patients Broad development program in neuroscience Continuous product improvement • Clinical trials utilizing mobiles, wearables and gaming devices • More sensitive, precise and objecti
Slide 44: Digital biomarker adherence during the pandemic largely unaffected
10 Digital biomarker adherence during the pandemic largely uneffected COVID-19 impacted clinical trial conduct in Q1/2 2020 • COVID-19 challenged clinical trials with 23 out of 25 pharma companies reporting moderate-high operational impact1) • Patients did not travel to sites and sites were shut dow
Slide 45: Digital biomarkers support clinical drug development
11 Digital biomarkers support clinical drug development Remote and objective assessments: e.g. Parkinson’s disease Daily at home assessment for 6 months Ph Ib digital biomarker results Smartphone sensor results correlate with clinical MDS-UPDRS scores (example tremor) • The digital biomarker test su
Slide 46: Parkinson's disease: Prasinezumab with signals of efficacy in Ph II
11 Parkinson’s disease: Prasinezumab with signals of efficacy in Ph II Ph IIb started to collect additional data on potential endpoints Ph II (PASADENA part 1) results at 52 weeks... ...and follow-up at 104 weeks Digital Motor Score Change in MDS-UPDRS total score • Ph II (PASADENA) study did not me
Slide 47: Towards regulatory acceptance of digital drug endpoints
Towards regulatory acceptance of digital drug endpoints: Collaboration across the scientific community & industry is key Building consensus through Creating alignment across the biopharmaceutical sector through Working with regulatory public-private partnerships, integrated cross-industry collaborat
Slide 48: Multiple sclerosis: Floodlight launched in US and EU
12 Multiple sclerosis: Floodlight launched in US and EU Building ecosystems to serve patients, society and scientific progress Value creation for patients Value creation for society • MS progression, often undetected by • Earlier intervention has the potential to current clinical scales improve heal
Slide 49: Jacqueline Law | Head of Corporate Strategy, Flatiron Health
Real world evidence to improve clinical R&D and patient care Jacqueline Law| Vice president, Head of Corporate Strategy, Flatiron Health 49
Slide 50: Digitalization impacting our entire value chain
Digitalization impacting our entire value chain Digital Infrastructure & Group functions 1 2 25 Treatment Clinical Regulatory & Manufacturing Support Early R&D Commercialisation Diagnosis Development Reimbursement & Distribution Physicians & Patients 3 4 5 9 10 11 12 13 14 24 17 21 26 27 12 19 23 6
Slide 51: Flatiron Health
Flatiron HealthⓇ Transform the way cancer is treated and researched around the globe by developing disruptive and durable technology and scientific solutions 3M >280 7 800 patient records community academic centers sites of care available for research, cancer centers partner on scientific with >2,00
Slide 52: High-priority investments for Flatiron
High-priority investments for Flatiron Real-World Evidence Clinical Research Expanding real-world data depth, Transforming clinical study execution breadth, and modalities to to bridge research and real-world support R&D, regulatory and access care Scientific Innovations Cancer Care Advancing novel
Slide 53: Flatiron curates high-quality RWD from EHRs and other sources
Flatiron curates high-quality RWD from structured and unstructured data in EHRs and other sources Structured Data Diagnosis Demographics Structured Data Structured Data EHR Drug Processing Visits Labs Processing Orders Unstructured Data Physician Notes Radiology Unstructured Unstructured Data Proces
Slide 54: Biopharma partners have used Flatiron RWD across product lifecycle
Biopharma partners have used Flatiron RWD to address evidence gaps and generate actionable insights across product lifecycle Discovery/ Clinical Regulatory 1 Translational 2 Development 3 Approval 4 Market Access 5 Post-Approval Characterizing Benchmark/ Real-world MOA / resistance Trial design unme
Slide 55: Flatiron collaborates to advance RWE for regulatory and HTA decision-making
Flatiron collaborates with many to advance RWE for regulatory and HTA decision-making With Regulators and HTA Policy & Advocacy Thought leadership With FDA Friends of Cancer Research Active participants in key RWE ● 5+ years of partnership (FoCR) stakeholder initiatives and ● 7 co-authored publicati
Slide 56: Case Study - KADCYLA: RWE led to label change in EU
13 Case Study - KADCYLA: RWE led to label change in EU SITUATION Updated EU label (SmPC or Summary of ○ Limited safety information in patients with low LVEF Product Characteristics) for KADCYLA ○ EMA required sponsor to submit data to support post-approval risk management plan ○ Prospective study wa
Slide 57: Case Study - TECENTRIQ: RWE reversed NICE decisions on coverage
14 Case Study - TECENTRIQ: RWE reversed NICE decisions on coverage SITUATION ○ NICE initially provided a negative draft assessment on the reimbursement for TECENTRIQ in locally advanced or metastatic “The committee accepted that NSCLC after chemotherapy overall survival at 5 years is likely to ○ The
Slide 58: Flatiron and FMI Clinico-Genomic Database (CGDB)
15 Flatiron and FMI have built a comprehensive real-world Clinco- Genomic Database (CGDB) to accelerate precision oncology CGDB Disease-specific clinical data ~87,000 patients Clinically meaningful cancer genomic data • Clinical depth/breadth that captures the • Proven portfolio of tests including s
Slide 59: Prospective Clinico-Genomic (PCG) data collection platform
16 Prospective Clinico-Genomic (PCG): A novel technology-enabled prospective data collection platform STUDY OBJECTIVES ○ To evaluate the feasibility of a scalable and prospective platform ○ To evaluate serial ctDNA as a predictor for response to therapy for “The PCG Study has the metastatic NSCLC pa
Slide 60: Recent high-impact use cases using Flatiron data
Recent high-impact use cases using Flatiron clinical and clinical-genomics data Use Case Description Presented at: Building external control arms from patient-level electronic health record data to replicate the randomized External Control IMBlaze370 control arm in metastatic colorectal cancer JCO 2
Slide 61: Flatiron and Komodo Health EHR-claims database
17 Flatiron and Komodo Health have developed an EHR-claims database to support a wider range of real-world research questions Real-world, longitudinal patient-level clinical data from Electronic Health Records (EHRs) from cancer clinics EHR-claims data can enhance our understanding of cancer patient
Slide 62: Flatiron clinico-scan data support real-world research and AI
18 Flatiron clinico-scan data support real-world research questions and AI algorithm development Clinico-scan data can support both real-world Clinical Genomic Scans research questions and AI algorithm development such as: ● Supplementing real-world outcomes like ● Over 1.2M scans from ~280,000 uniq
Slide 63: Flatiron technology solutions enable better patient experience
19 Flatiron technology solutions enable better patient experience, a healthier practice and smarter research Flatiron AssistTM supports evidence based care and streamlined clinical decision support: ● Biomarker-based treatment decision ● Biomarker-matched clinical trial options ● Support for biosimi
Slide 64: Flatiron is building a novel platform to bridge care and research
20 Flatiron is building a novel platform to bridge real-world care and clinical research Trial Site Selection Patient Data Data Cleaning & Data Design & Initiation Identification Collection Remote Monitoring Delivery Select product discovery spaces Trials Enablement Platform Data Management Platform
Slide 65: Steve Guise | Global Head, Pharma Informatics
Digital platforms accelerating development, manufacturing and commercialization Steve Guise| Global Head, Pharma Informatics 65
Slide 66: Digitalization impacting our entire value chain
Digitalization impacting our entire value chain Digital Infrastructure & Group functions 1 2 25 Treatment Clinical Regulatory & Manufacturing Support Early R&D Commercialization Diagnosis Development Reimbursement & Distribution Physicians & Patients 3 4 5 9 10 11 12 13 14 24 17 21 26 27 12 19 23 6
Slide 67: Our vision is anchored on a bold aspiration
Our vision is anchored on a bold aspiration Our customer experience is as transformative as our science Integrated healthcare play by 2030 Ecosystem play by 2026 Integrate different parts of the business in line with the One Roche Stakeholder play by 2023 Transform the healthcare ecosystem ambition
Slide 68: EpiCX: Technology and data backbone for digital customer enablement
21 EpiCX: Building a modern and interoperable technology and data backbone for digital customer enablement Product ecosystem Integrated cycle of customer intelligence Analytics Customer journey, needs/insights (e.g. Personify, One Customer, Next Best Actions) EpiCX customer & Customer content intell
Slide 69: EpiCX roll-out: Content management system and centralised services
21 EpiCX roll-out: Content management system (VVPM) and centralised services (Lab) for digital content production EpiCX dashboard: Content available and user statistics EpiCX dashboard EpiCX dashboard As of November 2021: • Launched VVPM in 100+ countries with approx 9400+ users trained • Active mat
Slide 70: Digitalization is changing the way we run our clinical trials
22 Digitalization is changing the way we run our clinical trials Clinical Trials Optimization Tool (CTO) • Single source of information to select and monitor sites • Across the industry almost 80% of all clinical trials fail to finish on time • CTO utilises machine learning for predictive ranking •
Slide 71: Enhancing patient experience through engagement capabilities
23 Enhancing patient experience through engagement capabilities and unified view of patient information Patient Assistance & Care Experience (PACE) • Field patient-facing roles have to hunt down information spread between between multiple systems, and having disjointed and inconsistent information •
Slide 72: Manufacturing individualized cell and gene therapies
24 Manufacturing individualized cell and gene & (incl. RNA) therapies Existing drug modalities One Batch – Many Patients Pure “Make to Stock” e.g. small molecules; antibodies Highly individualized Supply chain driven by new KPIs TMP and exception management New orchestration TCP therapies Wait time,
Slide 73: New digital capabilities enabling individualized therapies
24 New digital capabilities enabling individualized therapies Treatment Management Platform (TMP) Treatment Center Platform (TCP) Supply chain facing capability to manage & facilitate Facing the patients & treatment the supply chain centers Process facilitation of TCP, TMP and core ERP transactions
Slide 74: Roche response to COVID-19
25 Roche response to COVID-19 Roche IT infrastructure and capabilities to run the business as usual 74
Slide 75: Roche Information Solutions (RIS)
Roche Information Solutions (RIS) Bringing insights into action for better healthcare Moritz Hartmann| Global Head of Roche Information Solutions, Roche Diagnostics 75
Slide 76: Digitalization impacting our entire value chain
Digitalization impacting our entire value chain Digital Infrastructure & Group functions 1 2 25 Treatment Clinical Regulatory & Manufacturing Diagnosis Support Early R&D Commercialization Development Reimbursement & Distribution Physicians & Patients 3 4 5 9 10 11 12 13 14 24 17 21 26 27 12 19 23 6
Slide 77: Roche Diagnostics platform products & business models
Roche Diagnostics platform products & business models We provide platforms that power products across digital healthcare ecosystem Third-Party Applications Roche Applications & Algorithms SaaS App Marketplace PaaS Lab platform* cobas infinity edge NAVIFY Laboratories Healthcare Providers * in develo
Slide 78: Point of Care ecosystem: cobas infinity edge suite
26 Point of Care ecosystem Making truly decentralized testing a reality with cobas infinity edge suite cobas® infinity edge SMART cobas® infinity edge UNITE LabOPS POC cobas® infinity edge SCRIBE cobas® infinity POC Urgent Elderly Specialized Hospital GP Pharmacy Care Lab Care Home Clinic Center Cen
Slide 79: Point of Care ecosystem: Opportunity for Roche to disrupt healthcare
26 Point of Care ecosystem Opportunity for Roche to disrupt healthcare 3rd Party Apps Clinical decision Communication / support documentation Offline test entry Digital biomarkers Hospitals Pharmacies Vital Signs* Sensor reader* GPs cobas® pulse cobas® infinity edge SMART Utilisation of cobas & Enab
Slide 80: Point of Care ecosystem: Moving to cloud
26 Point of Care ecosystem Moving to cloud with cobas® infinity edge suite for seamless experience and secure connection to community-based POC devices UNITE SCRIBE SMART FUTURE VALUE SERVICES Connects primary care POC devices to Seamless integration of POC results Remote services for installation,
Slide 81: Digital Pathology ecosystem
27 Providing powerful ecosystem of AI tools to pathologists Digital Pathology ecosystem - an integrated solution for pathology and clinical decision support Whole Slide Scanner Platform & Software Applications Breast PHC DP 200 Roche Cancer Algorithms* Algorithms Multiplex* Panel1,2 Roche uPATH 3rd
Slide 82: Integrated oncology decision support
27 Integrated oncology decision support AI-enabled digital solutions for informed, efficient patient management NAVIFY® Digital Pathology NAVIFY® NAVIFY® PD-L1 Algorithm Mutation Profiler Tumor Board Interpretation Therapy options Radiology, pathology of biomarker & clinical trials & clinical data t
Slide 83: Q&A
Q&A
Slide 84: Doing now what patients need next
Doing now what patients need next